## Rajbharan Yadav

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4602016/publications.pdf

Version: 2024-02-01

22	528	15	22
papers	citations	h-index	g-index
23	23	23	637
all docs	docs citations	times ranked	citing authors

#	Article	lF	Citations
1	Two Mechanisms of Killing of Pseudomonas aeruginosa by Tobramycin Assessed at Multiple Inocula via Mechanism-Based Modeling. Antimicrobial Agents and Chemotherapy, 2015, 59, 2315-2327.	3.2	76
2	TGFÎ <sup>2</sup> 2 and TGFÎ <sup>2</sup> 3 isoforms drive fibrotic disease pathogenesis. Science Translational Medicine, 2021, 13, .	12.4	56
3	Novel Approach To Optimize Synergistic Carbapenem-Aminoglycoside Combinations against Carbapenem-Resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2015, 59, 2286-2298.	3.2	52
4	Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling. Antimicrobial Agents and Chemotherapy, $2017,61,\ldots$	3.2	31
5	Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	31
6	Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	27
7	Prescription Pattern of Antihypertensive Agents in T2DM Patients Visiting Tertiary Care Centre in North India. International Journal of Hypertension, 2012, 2012, 1-9.	1.3	26
8	Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	26
9	Conjugation of 10 kDa Linear PEG onto Trastuzumab Fab′ Is Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological Activity. Molecular Pharmaceutics, 2016, 13, 1229-1241.	4.6	25
10	Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21
11	Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	21
12	Bacillus Calmette–Guérin vaccine induces a selective serotonin reuptake inhibitor (SSRI)-resistant depression like phenotype in mice. Brain, Behavior, and Immunity, 2014, 42, 204-211.	4.1	20
13	Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans. AAPS Journal, 2015, 17, 1210-1223.	4.4	20
14	Single Intravenous Dose of Novel Flurbiprofen-Loaded Proniosome Formulations Provides Prolonged Systemic Exposure and Anti-inflammatory Effect. Molecular Pharmaceutics, 2016, 13, 3688-3699.	4.6	20
15	Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	18
16	Oncostatin M expression induced by bacterial triggers drives airway inflammatory and mucus secretion in severe asthma. Science Translational Medicine, 2022, 14, eabf8188.	12.4	17
17	Factors Influencing Magnitude and Duration of Target Inhibition Following Antibody Therapy: Implications in Drug Discovery and Development. AAPS Journal, 2013, 15, 717-727.	4.4	12
18	Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	10

#	Article	IF	CITATIONS
19	An integrated approach for characterizing immunogenic responses toward a bispecific antibody. MAbs, 2021, 13, 1944017.	5.2	9
20	Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling. European Journal of Pharmaceutical Sciences, 2017, 107, 32-44.	4.0	4
21	Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies. Pharmaceutics, 2022, 14, 970.	4.5	4
22	Prescribing pattern of antidiabetic drugs and achievement of glycemic control in T2DM patients tertiary care hospital in North India. International Journal of Diabetes in Developing Countries, 2013, 33, 140-146.	0.8	2